Gemfibrozil in hyperlipidaemia: an open, single blind trial.
No Thumbnail Available
Date
1990-02-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The efficacy of Gemfibrozil on S. lipid levels was studied in 36 middle aged subjects with type IIA, IIB, IV hyperlipidemia. Gemfibrozil was well tolerated in the dose of 1200 mg/day and no dropouts were attributable to its use. An overall reduction in total cholesterol (39.91%), total triglycerides (71.10%), VLDL triglycerides (62.97%). LDL cholesterol (45.57%) and apolipoprotein B levels (26.83%) were observed at 24 weeks. At the same time HDL cholesterol, and apolipoprotein A levels showed increases by 26.23% and 53.67% respectively. It is concluded that Gemfibrozil is an effective lipid lowering agent. Further long term studies are necessary to determine its optimal dosage and its long term safety in Indian subjects.
Description
Keywords
Citation
Varthakavi PK, Turakhia DP, Sharma SS, Salgaonkar DS, Nihalani KD, Joshi VR. Gemfibrozil in hyperlipidaemia: an open, single blind trial. Journal of the Association of Physicians of India. 1990 Feb; 38(2): 136-40